SEC Form 4 · accession 0001209191-18-055391
Allogene Therapeutics, Inc. · ALLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deborah M. Messemer
Director
Period of report
Oct 15, 2018
Accepted (ET)
Oct 17, 2018 · 5:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001737287
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 15, 2018 | J | 6,535 | — | A | 6,535 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Automatic conversion of an outstanding convertible promissory note in the principal amount of $100,000 into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at a conversion price of $15.30 per share.
- F2Securities held in the name of the Messemer Family Trust dated February 18, 2003.